Abstract
A solid lipid microparticle system containing budesonide was prepared by oil in water emulsification followed by spray drying. The solid lipid system was studied in terms of morphology, particle size distribution, crystallinity, thermal properties, aerosol performance, and dissolution/diffusion release. The microparticle system was also compared to conventional spray-dried crystalline and amorphous budesonide samples. The particle size distributions of the crystalline, amorphous, and solid lipid microparticles, measured by laser diffraction, were similar; however, the microparticle morphology was more irregular than the spray-dried drug samples. The thermal response of the solid lipid microparticles suggested polymorphic transition and melting of the lipid, glycerol behenate (at ~48°C and ~72°C). No budesonide melting or crystallisation peaks were observed, suggesting that the budesonide was integrated into the matrix. X-ray powder diffraction patterns of the crystalline and amorphous budesonide were consistent with previous studies while the solid lipid microparticles showed two peaks, at approximately 21.3 and 23.5 2θ suggesting the metastable sub-α and primarily β′ form. Analysis of the in vitro diffusion/dissolution of the formulations was studied using a flow through model and curves analysed using difference/similarity factors and fitted using the Higuchi model. Regression analysis of this data set indicated differences in the t 0.5, where values of 49.7, 35.3, and 136.9 min were observed for crystalline, amorphous, and the solid lipid microparticles, respectively. The aerosol performance (<5 μm), measured by multistage liquid impinger, was 29.5%, 27.3%, and 21.1 ± 0.6% for the crystalline, amorphous, and the solid lipid microparticles, respectively. This study has shown that solid lipid microparticles may provide a useful approach to controlled release respiratory therapy.
Similar content being viewed by others
References
Traini D, Young PM. Delivery of antibiotics to the respiratory tract for pulmonary infection: an update. Expert Opinion on Drug Delivery, Sep 2009, Vol. 6, No. 9 doi:10.1517/17425240903110710
Scheuch G, Kohlhaeufl MJ, Brand P, Siekmeier R. Clinical perspectives on pulmonary systemic and macromolecular delivery. Adv Drug Deliv Rev. 2006;58(9–10):996–1008.
Pritchard JN. The influence of lung deposition on clinical response 1. J Aerosol Med. 2001;14:S19–26.
Zeng XM, Martin GP, Marriott C. The controlled delivery of drugs to the lung. Int J Pharm. 1995;124(2):149–64.
Salama R, Traini D, Chan HK, Young PM. Recent advances in controlled release pulmonary therapy. Curr Drug Discov. 2009;6:404–14.
Trotta M, Debernardi F, Caputo O. Preparation of solid lipid nanoparticles by a solvent emulsitication-diffusion technique. Int J Pharm. 2003;257(1–2):153–60.
Dos Santos IR, Richard J, Pech B, Thies C, Benoit JP. Microencapsulation of protein particles within lipids using a novel supercritical fluid process. Int J Pharm. 2002;242(1–2):69–78.
Jaspart S, Piel G, Delattre L, Evrard B. Solid lipid microparticles: formulation, preparation, characterisation, drug release and applications. Expert Opin Drug Deliv. 2005;2(1):75–87.
Zhang LJ, Qian Y, Long CX, Chen Y. Systematic procedures for formulation design of drug-loaded solid lipid microparticles: selection of carrier material and stabilizer. Ind Eng Chem Res. 2008;47(16):6091–100.
Muller RH, Mader K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery—a review of the state of the art. Eur J Pharm Biopharm. 2000;50(1):161–77.
Jaspart S, Bertholet P, Piel G, Dogne JM, Delattre L, Evrard B. Solid lipid microparticles as a sustained release system for pulmonary drug delivery. Eur J Pharm Biopharm. 2007;65(1):47–56.
Sebti T, Amighi K. Preparation and in vitro evaluation of lipidic carriers and fillers for inhalation. Eur J Pharm Biopharm. 2006;63(1):51–8.
Cook RO, Pannu RK, Kellaway IW. Novel sustained release microspheres for pulmonary drug delivery. J Control Release. 2005;104(1):79–90.
Sanna V, Kirschvink N, Gustin P, Gavini E, Roland I, Delattre L, et al. Preparation and in vivo toxicity study of solid lipid microparticles as carrier for pulmonary administration. AAPS PharmSciTech. 2004;5(2):e27.
Pople P, Singh KK. Glyceryl behanate-monograph. In: Rowe RC, Sheskey PJ, Quinn ME, editors. Handbook of pharmaceutical excipients. 6th ed. London: Pharmaceutical Press; 2009. p. 286–8.
Dalpiaz A, Mezzena M, Scatturin A, Scalia S. Solid lipid microparticles for the stability enhancement of the polar drug N-6-cyclopentyladenosine. Int J Pharm. 2008;355(1–2):81–6.
Appendix XII B. Dissolution guidance on dissolution testing. British Pharmacopoeia Volume 2009. Norwich, UK: TSO; 2009.
Salama RO, Traini D, Chan HK, Young PM. Preparation and characterisation of controlled release co-spray dried drug-polymer microparticles for inhalation 2: evaluation of in vitro release profiling methodologies for controlled release respiratory aerosols. Eur J Pharm Biopharm. 2008;70(1):145–52.
Moss OR. Simulants of lung interstitial fluid. Health Phys. 1979;36(3):447–8.
Davies NM, Feddah MR. A novel method for assessing dissolution of aerosol inhaler products. Int J Pharm. 2003;255(1–2):175–87.
Section 2.9.18—appendix XII C. Consistency of formulated preparations for inhalation. British Pharmacopoeia, 2009.
Tursilli R, Piel G, Delattre L, Scalia S. Solid lipid microparticles containing the sunscreen agent, octyl-dimethylaminobenzoate: effect of the vehicle. Eur J Pharm Biopharm. 2007;66(3):483–.
Tajber L, Corrigan DO, Corrigan OI, Healy AM. Spray drying of budesonide, formoterol fumarate and their composites—I. Physicochemical characterisation. Int J Pharm. 2009;367(1–2):79–85.
Velaga SP, Berger R, Carlfors J. Supercritical fluids crystallization of budesonide and flunisolide. Pharm Res. 2002;19(10):1564–71.
Brubach JB, Jannin V, Mahler B, Bourgaux C, Lessieur P, Roy P, et al. Structural and thermal characterization of glyceryl behenate by X-ray diffraction coupled to differential calorimetry and infrared spectroscopy. Int J Pharm. 2007;336(2):248–56.
Souto EB, Mehnert W, Muller RH. Polymorphic behaviour of Compritol888 ATO as bulk lipid and as SLN and NLC. J Microencapsul. 2006;23(4):417–33.
Eldem T, Speiser P, Altorfer H. Polymorphic behavior of sprayed lipid micropellets and its evaluation by differential scanning calorimetry and scanning electron microscopy. Pharm Res. 1991;8(2):178–84.
Rao M, Ranpise A, Borate S, Thanki K. Mechanistic evaluation of the effect of sintering on Compritol 888 ATO matrices. AAPS PharmSciTech. 2009;10(2):355–60.
Pham S, Wiedmann TS. Note: dissolution of aerosol particles of budesonide in Survanta, a model lung surfactant. J Pharm Sci. 2001;90(1):98–104.
Moore JW, Flanner HH. Mathematical comparison of dissolution profiles. Pharm Tech. 1996;20:64–75.
Guidence for industry; Dissolution testing of immediate release solid dosage forms. In: Administration FaD, editor. August 1997.
Zhang J, Ebbens S, Chen X, Jin Z, Luk S, Madden C, et al. Determination of the surface free energy of crystalline and amorphous lactose by atomic force microscopy adhesion measurement. Pharm Res. 2006;23(2):401–7.
Newell HE, Buckton G, Butler DA, Thielmann F, Williams DR. The use of inverse phase gas chromatography to measure the surface energy of crystalline, amorphous, and recently milled lactose. Pharmaceut Res. 2001;18(5):662–6.
Smith IJ, Parry-Billings M. The inhalers of the future? A review of dry powder devices on the market today. Pulm Pharmacol Ther. 2003;16(2):79–95.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mezzena, M., Scalia, S., Young, P.M. et al. Solid Lipid Budesonide Microparticles for Controlled Release Inhalation Therapy. AAPS J 11, 771–778 (2009). https://doi.org/10.1208/s12248-009-9148-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1208/s12248-009-9148-6